$MSDL

Morgan Stanley Direct Lending Fund (MSDL): Results of Operations and Financial Condition

Morgan Stanley Direct Lending Fund (MSDL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d156013dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Morgan Stanley Direct Lending Fund Announces June 30, 2026 Financial Results and Declares Third Quarter 2026 Regular Dividend of $0.45 per Share NEW YORK, NY, August 6, 2026 — Morgan Stanley Direct Lending Fund (NYSE: MSDL)

Original reporting
Published Aug 6, 2026, 8:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MSDL
Neutral
medium confidence
Mentioned
$MSDL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MSDLNeutralMed
01

Why it matters

Q2 results show modest NII per share decline ($0.45 vs $0.47) and NAV per share down to $19.50, while the Board declared a regular $0.45/share dividend payable around Oct 23, 2026. The company also extended its Truist Credit Facility and issued $350M of 6.10% notes due July 2031 after quarter end.

02

Market read

Traders can update valuation and income expectations using the reported NII, NAV, non-accrual level, and the declared dividend, plus financing term changes.

03

What to watch

The filing notes a Truist Credit Facility extension to April 2030 and final maturity April 2031, plus a subsequent $350M 6.10% notes issuance, which may affect future leverage and interest expense trajectory.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 6, 2026, ahead of Aug 7 conference call

Background

Morgan Stanley Direct Lending Fund (MSDL) is an externally managed business development company that reports quarterly results and declares regular dividends.

Company-level read

Ticker impact

$MSDLNeutralMedium confidence
Context

MSDL reported Q2 ended June 30, 2026 results, including net investment income of $38.2M ($0.45/share) and NAV $19.50/share.

Expected impact

Near-term sentiment likely neutral to mildly positive due to the $0.45/share regular dividend, offset by lower NII and NAV decline.

Evidence & confidence

The filing provides concrete quarterly datapoints (NII, NAV, EPS, non-accrual share) plus a declared dividend and a post-quarter debt issuance, but no explicit guidance or surprise event beyond the reported quarter.

Market effects

BDC-style credit funds may see read-across from reported non-accrual share (2.9% of amortized cost) and floating-rate exposure (99.6%).

Limited, as the disclosure is company-specific and not tied to a macro policy decision.

Low, as the drivers are internal portfolio performance and financing terms.

Counterpoint

The NAV decline (to $19.50 from $19.81) could be temporary if non-accrual positions normalize, while the dividend remains unchanged at $0.45/share.

Key entities

  • Morgan Stanley Direct Lending Fund

    Subject of the SEC 8-K, reporting Q2 2026 financial results and declaring the Q3 2026 regular dividend.

  • Capstone Lending LLC (Capstone JV)

    Joint venture ramped during the quarter; about 52.3% of total capital commitments were called as of June 30, 2026.

  • Truist Credit Facility

    Amended April 23, 2026 to extend termination to April 2030 and final maturity to April 2031.

  • BNP Funding Facility

    Part of total principal debt outstanding as of June 30, 2026 ($351.0M outstanding).

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.